1.Klebsiella pneumoniae bacteremia and renosplenic abscesses without intestinal symptoms as the initial manifestations of non-steroidal anti-inflammatory drug-induced colitis: a rare case report.
Huang HL1, Lu PL, Lin CY, Chen YH, Kuo CH, Lin WR. BMC Gastroenterol. 2013 Sep 22;13:139. doi: 10.1186/1471-230X-13-139.
BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs), the most widely prescribed drugs in the world, can cause gastrointestinal damage, including colitis. However, the prevalence of NSAID-induced colitis is unknown because the disease is often asymptomatic.
2.Alternate endpoints and clinical outcome assessments in pediatric ulcerative colitis registration trials.
Sun H1, Lee JJ, Papadopoulos EJ, Lee CS, Nelson RM, Sachs HC, Rodriguez WJ, Mulberg AE. J Pediatr Gastroenterol Nutr. 2014 Jan;58(1):12-7. doi: 10.1097/MPG.0000000000000186.
OBJECTIVES: Presently, there is no consensus on endpoint measures to assess clinical outcomes for pediatric ulcerative colitis (UC). This study reviewed the endpoints used in the registration trials of approved drugs for pediatric UC.
3.Balsalazide Potentiates Parthenolide-Mediated Inhibition of Nuclear Factor-κB Signaling in HCT116 Human Colorectal Cancer Cells.
Kim HY1, Kim SL2, Park YR2, Liu YC2, Seo SY1, Kim SH1, Kim IH1, Lee SO1, Lee ST2, Kim SW2. Intest Res. 2015 Jul;13(3):233-41. doi: 10.5217/ir.2015.13.3.233. Epub 2015 Jun 9.
BACKGROUND/AIMS: Balsalazide is an anti-inflammatory drug used in the treatment of inflammatory bowel disease. Balsalazide can reduce inflammatory responses via several mechanisms, including inhibition of nuclear factor-κB (NF-κB) activity. Parthenolide (PT) inhibits NF-κB and exerts promising anticancer effects by promoting apoptosis. The present investigated the antitumor effects of balsalazide, combined with PT, on NF-κB in a representative human colorectal carcinoma cell line, HCT116.